Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III NSCLC.
Non-Small Cell Lung Cancer
DRUG: Docetaxel/Carboplatin/Bevacizumab/Erlotinib|DRUG: Docetaxel/Carboplatin
Disease-free Survival, The length of time, in months, that patients were alive from the end of their treatment without any signs or symptoms of their disease., 1 year
Safety, Adverse Events occuring in \>15% of patients, 2 years|2-year Survival, Proportion of patients known to still be alive 2 years after coming on study, 24 months|Overall Survival (OS), The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death, 18 months
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III NSCLC.